Reliance Life Sciences (RLS) is part of the Reliance Group of companies. RLS participates primarily in medical biotechnology business opportunities; with key initiatives in biopharmaceuticals, pharmaceuticals, clinical research services, regenerative medicine and molecular medicine services.

RLS has launched three of the world’s first biosimilars and has the highest number of biosimilars under development globally. It has the distinction of being the only manufacturer of plasma proteins in South Asia. RLS has catalyzed the emergence of regenerative medicine in the country and has the highest experience with stem cell transplants in India. RLS is one of the few centres in the world offering a specialized range of tests in molecular medicine.

RLS operates state-of-the-art facilities in the life sciences domain. The flagship facility is the Dhirubhai Ambani Life Sciences Centre (DALC) in Navi Mumbai, India. Spread over 20 acres, DALC is among the most diverse and integrated life sciences campuses in the world housing world-scale and world-class manufacturing facilities approved by Indian and international regulatory agencies. A second facility is in Bengaluru, India, for clinical pharmacology and clinical data management.

Today RLS is a fully-integrated life sciences industry player with in-house capabilities in research, pre-clinical and clinical development, process development, commercial-scale manufacturing and marketing.